About: Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
Creator	Azhar, Esam Li, Xuguang Hashem, M Abbas, Ayman Al-Amri, Sawsan Al-Muhanna, Muhanna Alghamdi, Abrar Alhabbab, Rowa Anwar, & Sanki, Mohammad Siddiq, Loai
topic	covid:76418514384003ef87ee3e6922525db0b8bf0bd3#this
Source	Medline; PMC
abstract	MERS-coronavirus is a novel zoonotic pathogen which spread rapidly to >25 countries since 2012. Its apparent endemicity and the wide spread of its reservoir host (dromedary camels) in the Arabian Peninsula highlight the ongoing public health threat of this virus. Therefore, development of effective prophylactic vaccine needs to be urgently explored given that there are no approved prophylactics or therapeutics for humans or animals to date. Different vaccine candidates have been investigated but serious safety concerns remain over protein or full-length spike (S) protein-based vaccines. Here, we investigated the immunogenicity of naked DNA vaccines expressing different fragments of MERS-CoV S protein in mice. We found that plasmids expressing full-length (pS) or S1-subunit (pS1) could induce significant levels of S1-specific antibodies (Abs) but with distinct IgG isotype patterns. Specifically, pS1 immunization elicited a balanced Th1/Th2 response and generally higher levels of all IgG isotypes compared to pS vaccination. Interestingly, only mice immunized with pS1 demonstrated significant S1-specific cellular immune response. Importantly, both constructs induced cross-neutralizing Abs against multiple strains of human and camel origins. These results indicate that vaccines expressing S1-subunit of the MERS-CoV S protein could represent a potential vaccine candidate without the possible safety concerns associated with full-length protein-based vaccines.
has issue date	2017-03-23(xsd:dateTime)
bibo:doi	10.1038/srep44875
bibo:pmid	28332568
has license	cc-by
sha1sum (hex)	76418514384003ef87ee3e6922525db0b8bf0bd3
schema:url	https://doi.org/10.1038/srep44875
resource representing a document's title	Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
has PubMed Central identifier	PMC5362948
has PubMed identifier	28332568
schema:publication	Sci Rep
resource representing a document's body	covid:76418514384003ef87ee3e6922525db0b8bf0bd3#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/76418514384003ef87ee3e6922525db0b8bf0bd3
is schema:about of	named entity 'IMMUNOGENICITY' named entity 'higher' named entity 'naked DNA' named entity 'vaccines' named entity 'subunit' named entity 'Abs' named entity 'Spike' named entity 'CANDIDATE' named entity 'RESPONSE' named entity 'MERS-COV S PROTEIN' named entity 'THREAT' named entity 'PROPHYLACTIC VACCINE' named entity 'VACCINE' named entity 'CROSS' named entity 'COULD REPRESENT' named entity 'PLASMIDS' named entity 'IGG' named entity 'PATTERNS' named entity 'PROTEIN ' named entity 'PS1' named entity 'CONCERNS' named entity 'DISTINCT' named entity 'SPIKE' named entity 'INVESTIGATED' named entity 'INDUCE' named entity 'NEEDS' named entity 'COMPARED' named entity 'TH1' named entity 'ISOTYPE' named entity 'VACCINES' named entity 'ANIMALS' named entity 'ENDEMICITY' named entity 'INDUCED' named entity 'IMMUNIZATION' named entity 'BALANCED' named entity 'FOUND' named entity 'POSSIBLE' named entity 'DEMONSTRATED' named entity 'THESE' named entity 'CELLULAR IMMUNE RESPONSE' named entity 'GIVEN' named entity 'ORIGINS' named entity 'WIDE SPREAD' named entity 'VACCINE CANDIDATE' named entity 'PUBLIC HEALTH' named entity 'DATE' named entity 'SUBUNIT' named entity 'PROTEIN ' named entity 'EFFECTIVE' named entity 'BASED' named entity 'VACCINATION' named entity 'RESULTS' named entity 'HUMANS' named entity '28S' named entity 'CAMELS' named entity 'PROTEIN' named entity 'HERE' named entity 'BUT' named entity 'ARABIAN PENINSULA' named entity 'ELICITED' named entity 'IMMUNOGENICITY' named entity 'RESERVOIR' named entity 'SIGNIFICANT' named entity 'DNA VACCINES' named entity 'MERS-COV' named entity 'OPEN' named entity 'BASED' named entity 'HUMAN' named entity 'IMMUNIZED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software